Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926537 | 0.90 | CTSA (0.46) | CTSACYP26A1PTPN22FLT1FLT4 | |
| SCHEMBL5926506 | 0.87 | CYP26A1 (0.46) | CTSACYP26A1PTPN22 | |
| SCHEMBL5927464 | 0.87 | ITGB1 (0.49) | — | |
| SCHEMBL5926616 | 0.86 | MMP1 (0.49) | CTSACYP26A1 | |
| SCHEMBL5927193 | 0.82 | CTSA (0.48) | CTSACYP26A1SUCNR1UTS2R | |
| SCHEMBL5926716 | 0.80 | CYP26A1 (0.48) | CTSACYP26A1SUCNR1UTS2R | |
| SCHEMBL5926540 | 0.79 | CTSA (0.47) | CTSACYP26A1SUCNR1UTS2R | |
| SCHEMBL5926872 | 0.79 | ADAMTS5 (0.44) | CTSACYP26A1SUCNR1UTS2R | |
| SCHEMBL5927179 | 0.78 | CTSA (0.45) | CTSACYP26A1SUCNR1 | |
| SCHEMBL5927232 | 0.77 | CYP26A1 (0.44) | CTSACYP26A1UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885CYP26A1 526/4885PTPN22 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.